Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes
Background and aims: Although landmark clinical trials have demonstrated an increased risk for genitourinary infection (GUI) after initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy that led to an FDA label warning, real world findings have been inconsistent and evidence specifi...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Llibre |
| Publicat: |
SAGE Publishing,
2021-03-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Còpia 1 | Disponible |